Literature DB >> 27734458

Alcohol septal ablation in hypertrophic cardiomyopathy utilizing a longitudinal 17-year study (mean 10.8). Observation follow-ups taken at a single medical centre.

Andrzej Wojtarowicz1, Zdzisława Kornacewicz-Jach.   

Abstract

BACKGROUND: Alcohol septal ablation (ASA) is a method of treatment in obstructive hypertrophic car-diomyopathy (HOCM), but there is little data on the long-term results of ASA and the natural course after treatment. The aim of the study was to evaluate the results of ASA in HOCM in multiannual observation, and its impact on patient survival, exercise capacity, electrical complications, and changes in the anatomy and function of the heart.
METHODS: The study evaluated 47 patients with HOCM with a high left ventricular outflow tract (LVOT gradient) treated between 1997 and 2014 with ASA. Annual examinations evaluated the clinical condi-tion, at rest and with exercise electrocardiogram, Holter monitoring, echocardiography, the evolution of HOCM towards the dilated form, and the frequency of pacemaker implantation.
RESULTS: The analysis included data from 34 patients under observation for 3 to 17 (mean 10.8) years. Their age at procedure was 21-65, a mean of 47 years. All patients had permanently reduced LVOT gradient with a mean of 77.36 ± 35.46 to 11.40 ± 10.85 and showed improvement in the performance I to II New York Heart Association. Two out of five deaths had possible cardiac etiology. Fifteen patients received a pacemaker or cardioverter implants. In 4 subjects the long-term observation revealed new wall contractility abnormalities, interpreted as a shift of HOCM to the dilated form.
CONCLUSIONS: Alcohol septal ablation permanently eliminated the gradient in LVOT and improved the performance of patients, however it did not prevent a shift of HOCM to the dilated form. Pacemaker implantations are relatively frequent. (Cardiol J 2017; 24, 2: 125-130).

Entities:  

Keywords:  alcohol septal ablation; arrhythmias and conduction abnormalities; heart failure; hypertrophic obstructive cardiomyopathy

Mesh:

Substances:

Year:  2016        PMID: 27734458     DOI: 10.5603/CJ.a2016.0089

Source DB:  PubMed          Journal:  Cardiol J        ISSN: 1898-018X            Impact factor:   2.737


  3 in total

1.  Results of Ten-Year Follow-Up of Alcohol Septal Ablation in Patients with Obstructive Hypertrophic Cardiomyopathy.

Authors:  Maksim Kashtanov; Anastasiya Rzhannikova; Sergey Chernyshev; Lev Kardapoltsev; Eduard Idov; Sergey Berdnikov
Journal:  Int J Angiol       Date:  2018-10-29

2.  Alcohol septal ablation vs myectomy for symptomatic hypertrophic obstructive cardiomyopathy: Systematic review and meta-analysis.

Authors:  Mohammed Osman; Babikir Kheiri; Khansa Osman; Mahmoud Barbarawi; Hani Alhamoud; Fahad Alqahtani; Mohamad Alkhouli
Journal:  Clin Cardiol       Date:  2018-11-29       Impact factor: 2.882

3.  Serum N-terminal pro-B-type natriuretic peptide levels are associated with left atrial dilation, resting left ventricular outflow tract gradient, and pulmonary hypertension in patients with hypertrophic cardiomyopathy.

Authors:  Adam Gębka; Renata Rajtar-Salwa; Artur Dziewierz; Paweł Petkow-Dimitrow
Journal:  Postepy Kardiol Interwencyjnej       Date:  2020-02-09       Impact factor: 1.426

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.